Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy

Osteolytic bone destruction caused by increase of osteolytic activity is a major manifestation of multiple myeloma (MM). Pamidronate (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate) inhibits osteoclastic activity and reduces bone resorption. Since October 1995 the efficacy of pamidronate is evalua...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Acta Poloniae pharmaceutica 2000-11, Vol.57 Suppl, p.113-116
Hauptverfasser:	Kraj, M, Pogłód, R, Pawlikowski, J, Maj, S, Nasiłowska, B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Bone Resorption - psychology Calcium - urine Diphosphonates - therapeutic use Female Humans Male Middle Aged Multiple Myeloma - complications Multiple Myeloma - drug therapy Osteolysis - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!